Abattis alligns talent and Mike Withrow moves to International Business Advisor
Vancouver, BC, / ACCESSWIRE / January 27, 2015 / Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that effective February 1st. Mike Withrow will move from his role as CEO and Chairman to a new position as International Business Advisor where he has identified opportunities in legal jurisdictions that are strategic to Abattis. The board is in discussions with its members and will be appointing a new CEO shortly. The CEO and Chairman positions will be filled with someone who has good relations with Health Canada and can been seen as a good partner by Health Canada.
The board thanks Mr. Withrow for his vision in the founding and development of Abattis Bioceuticals Corp., and for the energy he has devoted to bringing the company to a leadership position in the field of botanical medicine analytics and production in the biotech sector. Mr. Withrow will, in his new role as International Business Advisor he will continue to nurture strategic partnerships in select countries that enhance the corporation’s activities and maximize value of the Abattis technologies and assets.
Mr. Withrow was quoted as saying “As a significant shareholder of Abattis, I believe this is the best thing for the company as it moves through its next stage of growth. I look forward to bringing strategic international business partnerships to the company. Now is the time to bring in a CEO who has a proven track record in managing revenue and rapid growth.”
As we align our talent Jaouad Fichtali, who was appointed in the role of Chief Technology Officer (CTO) of Abattis effective November 14, 2014, will be assuming a more focused role as Advisor of Extraction IP effective immediately. This will allow the company to focus on and deploy its extraction technology with foreign partners.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.
ON BEHALF OF THE BOARD
Michael Withrow, President & CEO
For further information, contact IR for Abattis Bioceuticals Corp. at (604) or at firstname.lastname@example.org.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
SOURCE: Abattis Bioceuticals Corp.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com